U.S. Stock Futures Edge Up as S&P 500 Nears All-Time High
U.S. stock futures edged higher Tuesday night as investors looked to see whether the benchmark index could reclaim its all-time high. Futures on the Nasdaq 100 (NDX), the Dow Jones Industrial Average (DJIA), and the S&P 500 (SPX) were up 0.04%, 0.03%, and 0.02%, respectively, at 12:54 a.m. EST, June 25.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Israel and Iran have officially agreed to a ceasefire, lifting both the S&P 500 and the Nasdaq 100. With missile threats easing, both nations have started preparing to reopen their airspace.
On Tuesday, the S&P 500 climbed 1.11% as oil prices fell amid optimism that the ceasefire would last. The index is now trading less than 1% below its record high. Meanwhile, the Nasdaq Composite gained more than 1%, and the Dow Jones climbed more than 500 points.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
Wainwright sets over $100 target for Nektar on ‘paradigm-shifting' data
H.C. Wainwright analyst Arthur He raised the firm's price target on Nektar (NKTR) to $120 from $6.50 and keeps a Buy rating on the shares. The company this morning announced positive results from the induction period of its ongoing Phase 2b REZOLVE-AD study evaluating rezpegaldesleukin in patients with moderate to-severe atopic dermatitis, the analyst tells investors in a research note. Citing the drug's 'highly differentiated mechanism of action' compared to currently approved therapies, H.C. Wainwright believes rezpeg 'has the potential to reshape the treatment landscape' for atopic dermatitis. The firm expects to see further improvement in efficacy in the next clinical data update when the 36-week maintenance data is expected to be reported in Q1 of 2026. Nektar says a 'paradigm-shifting' atopic dermatitis drug 'has arrived.' The stock in midday trading is up 134%, or $12.82, to $22.36. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on NKTR: Disclaimer & DisclosureReport an Issue Nektar price target raised to $120 from $6.50 at H.C. Wainwright Why Is Nektar Therapeutics Stock (NKTR) Up 110% Today? Nektar jumps 130% to $21.90 after atopic dermatitis study success Nektar Therapeutics Announces Positive Phase 2b Trial Results Nektar's rezpegaldesleukin meets endpoints in Phase 2b atopic dermatitis trial Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
38 minutes ago
- Yahoo
No Ad Comm ‘not necessarily positive' for Capricor, says Roth Capital
Roth Capital analyst Boobalan Pachaiyappan tells investors in a research note that the FDA's intention not to require an Ad Comm 'at this time' for deramiocel for the treatment of cardiomyopathy associated with Duchenne Muscular Dystrophy 'may not necessarily be positive news,' and that it believes a promissory Ad Comm meeting would be positive, as a potential positive Ad Comm panel vote would put pressure on the new leadership to approve deramiocel in its current form. The firm reiterates a Buy rating and $31 price target on Capricor shares. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on CAPR: Disclaimer & DisclosureReport an Issue Capricor's deramiocel moves ahead without AdCom, says H.C. Wainwright HHS spokesperson tells Reuters FDA 'actively re-evaluating' Capricor AdCom Capricor Therapeutics provides regulatory update on Deramiocel BLA Roth says 'excessive' Capricor selloff due to 'investor overreaction' Capricor selloff brings buying opportunity, says H.C. Wainwright Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Why AeroVironment Stock Is Soaring Today
AeroVironment topped expectations for the quarter, and ended its fiscal year with its largest bookings total in history. The company has established itself in the defense sector, and has opportunities to grow from here as it moves into new markets. 10 stocks we like better than AeroVironment › AeroVironment (NASDAQ: AVAV) topped quarterly expectations and closed out its fiscal year with its highest total bookings on record. Investors are pleased, sending shares of the drone manufacturer up 26% as of 10:30 a.m. ET. AeroVironment is a manufacturer of small-to-midsized military-grade unmanned aerial vehicles (UAVs). The company's products have demonstrated their value on the battlefield in Ukraine, attracting a lot of interest among investors. The latest results appear to justify that interest. AeroVironment earned $1.61 per share in its fiscal fourth quarter ending April 30 on revenue of $275.1 million, easily topping Wall Street's expectation for $1.38 in earnings on sales of $242 million. "AeroVironment finished out fiscal year 2025 with a remarkable fourth quarter, which included record revenue, significantly higher profits, and a robust backlog nearly double that from fiscal year 2024," CEO Wahid Nawabi said in a statement. The company closed the year with $1.2 billion in total bookings, creating a solid pipeline of future revenue. In the past few years, AeroVironment has gone from a company with a promising suite of technologies to a battle-tested contractor. The company is poised to broaden the scale of its offerings in the years to come, both with larger, more complex UAVs and, thanks to the acquisition of BlueHalo, new space and sea-based systems. If there is a knock on the stock today, it is the relatively rich valuation for a defense contractor. AeroVironment trades at 63 times expected earnings, well above the 17 to 20 times range of more established contractors, including General Dynamics, Northrop Grumman, and Lockheed Martin. But AeroVironment is starting from a smaller base and has more opportunities to grow than those larger rivals in the years to come. For investors who can handle the potential volatility that comes with higher valuations, AeroVironment looks like a winner in the defense-tech sector. Before you buy stock in AeroVironment, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and AeroVironment wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $689,813!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $906,556!* Now, it's worth noting Stock Advisor's total average return is 809% — a market-crushing outperformance compared to 175% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Lou Whiteman has positions in General Dynamics and Lockheed Martin. The Motley Fool has positions in and recommends AeroVironment. The Motley Fool recommends Lockheed Martin. The Motley Fool has a disclosure policy. Why AeroVironment Stock Is Soaring Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
